← Every company
Ultragenyx Pharmaceutical Inc Patents
What Ultragenyx Pharmaceutical Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
RARE on carbonthat →Filings on file
39
Granted
0
Still pending
39
Filed under
4 names
39 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| METHODS FOR IMPROVED THERAPEUTIC USE OF RECOMBINANT AAVA61K 39/3955, C12N 15/86, A61P 43/00, A61P 37/06, A61K 31/5377, A61K 31/573, A61K 31/675, A61K 31/69, A61K 38/1825, A61K 38/36, A61K 38/37, A61K 38/44, A61K 38/45, A61K 38/46, A61K 38/465, A61K 38/48, A61K 38/4873, A61K 38/53, A61K 45/06, A61K 48/0083, C12N2750/14143, A61K2300/00Filed as Ultragenyx Pharmaceutical Inc.2026-01-07Barbara Anne Sullivan | pending |
| COMPOSITIONS AND METHODS FOR REDUCING HOST CELL PROTEINS IN RECOMBINANT ADENO-ASSOCIATED VIRUS PREPARATIONSC12N 7/00, B01D 15/166, B01D 15/3804, B01D 15/426, C12N 15/86, C12N2750/14143, C12N2750/14151Filed as Ultragenyx Pharmaceutical Inc.2025-12-19Wenjun Di | pending |
| FORMULATIONS COMPRISING RECOMBINANT AAV AND METHODS OF ADMINISTERING THE SAMEA61K 48/0033, A61K 48/005, A61K 38/45, A61K 48/0075, C12N 7/00, C12N 15/86, C12Y 207/11022Filed as Ultragenyx Pharmaceutical Inc.2025-11-17Heather Lau | pending |
| GENE THERAPY FOR TREATING PROPIONIC ACIDEMIAA61K 48/005, C12N 15/86, A01K2217/072, A01K2227/105, A61K 38/53, A61K 48/0091, C12N 9/93, C12N2750/14143, C12N2800/22, C12N2830/008, C12N2830/50, C12Q 1/6883, C12Y 604/01003Filed as Ultragenyx Pharmaceutical Inc.2025-10-21Matthew Scott Fuller | pending |
| HUMAN FGF23-BINDING ANTIBODIES WITH IMPROVED AFFINITY AND EFFICACYC07K 16/22, C07K 16/244, A61P 7/00, A61K2039/505, C07K2317/21, C07K2317/24, C07K2317/33, C07K2317/34, C07K2317/56, C07K2317/565, C07K2317/567, C07K2317/76, C07K2317/92, C07K2317/94Filed as Ultragenyx Pharmaceutical Inc.2025-09-08Mark Fox | pending |
| CRYSTALLINE FORMS OF SIALIC ACID DERIVATIVES AND METHODS FOR THEIR USEC07H 13/06Filed as Ultragenyx Pharmaceutical Inc.2025-08-11Jean Carol BAUM | pending |
| SIALYLATED GLYCOPROTEIN COMPOSITION AND USES THEREOFA61P 3/00, A61K 38/47, C12N 9/2402, A61P 43/00, A61K 9/0019, A61K 45/06, C12N 9/24, C12N 9/2468, C12N 15/67, C12Y 302/01031Filed as Ultragenyx Pharmaceutical Inc.2025-07-17Steven JUNGLES | pending |
| METHOD OF PRODUCING SOLUBLE MICRODYSTROPHIN PROTEIN AND USES OF THE SAMEC07K 14/47, C07K 14/4708, C07K 1/145, C07K 1/22, G01N 33/6854, G01N 33/6893, G01N2333/47Filed as Ultragenyx Pharmaceutical Inc.2025-06-20Jaclyn Cadaoas | pending |
| GENE THERAPY CONSTRUCTS FOR TREATING WILSON DISEASEA61K 48/005, C12N 15/86, A61P 43/00, A61K 48/0058, C12N 9/6421, C12N2750/14141, C12N2750/14143Filed as Ultragenyx Pharmaceutical Inc.2025-05-20Christine Livingston | pending |
| MULTI-STEP FILTRATION AND CLARIFICATION METHODS FOR RECOMBINANT ADENO-ASSOCIATED VIRUS PURIFICATIONFiled as ULTRAGENYX PHARMACEUTICAL INC.2025-04-21DENNIS PERRY CHEN | pending |
| DOSING REGIMENS FOR ANTISENSE TREATMENT OF ANGELMAN SYNDROMEFiled as ULTRAGENYX PHARMACEUTICAL INC.2025-04-10OLUKEMI AJAYI OLUGEMO | pending |
| SIALYLATED GLYCOPROTEIN COMPOSITIONS AND USES THEREOFFiled as Ultragenyx Pharmaceutical Inc.2025-03-10Steven JUNGLES | pending |
| NOVEL ANION-EXCHANGE CHROMATOGRAPHY METHODS FOR SEPARATION OF EMPTY FROM FULL RECOMBINANT ADENO-ASSOCIATED VIRUS PARTICLESB01D 15/363, B01D 15/166, B01D 15/1864, B01D 15/203, B01D 15/424, B01J 41/20, C12N 7/00, C12N 15/86, C12N2750/14122, C12N2750/14143, C12N2750/14151Filed as Ultragenyx Pharmaceutical Inc.2025-02-07Wenjun Di | pending |
| LYOPHILIZED LIPID NANOPARTICLES AND METHODS OF THEIR USEA61K 9/5123, A61K 9/19, A61K 31/7105, A61K 38/1709, A61K 38/45, A61K 38/47Filed as Ultragenyx Pharmaceutical Inc.2025-02-07ISAIAS PRADO | pending |
| DOSING REGIMENS FOR ANTISENSE TREATMENT OF ANGELMAN SYNDROMEFiled as Ultragenyx Pharmaceutical Inc.2025-01-17Olukemi Ajayi Olugemo | pending |
| COMPOSITIONS OF TRIGLYCERIDES AND USES THEREOFA61K 9/143, A61K 31/20, A61K 31/23, A61P 9/10, A61P 3/00, Y02A 50/30, A61P 21/02, A61P 25/08, A61K 9/146, A61K 9/16, A61K 9/1611, A61K 9/1652, A61K 9/1664, A61K 31/201, A61K 31/202Filed as Ultragenyx Pharmaceutical Inc.2024-12-26John KLOPP | pending |
| COMPOSITIONS OF TRIGLYCERIDES AND USES THEREOFA61K 9/143, A61K 31/20, A61K 31/23, A61P 9/10, A61P 3/00, Y02A 50/30, A61P 21/02, A61P 25/08, A61K 9/146, A61K 9/16, A61K 9/1611, A61K 9/1652, A61K 9/1664, A61K 31/201, A61K 31/202Filed as Ultragenyx Pharmaceutical Inc.2024-12-26John KLOPP | pending |
| COMPOSITIONS OF TRIGLYCERIDES AND USES THEREOFA61K 9/143, A61K 31/20, A61K 31/23, A61P 9/10, A61P 3/00, Y02A 50/30, A61P 21/02, A61P 25/08, A61K 9/146, A61K 9/16, A61K 9/1611, A61K 9/1652, A61K 9/1664, A61K 31/201, A61K 31/202Filed as Ultragenyx Pharmaceutical Inc.2024-12-26John KLOPP | pending |
| COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH UBE3A OVEREXPRESSIONFiled as ULTRAGENYX PHARMACEUTICAL INC.2024-12-12ANDRZEJ SWISTOWSKI | pending |
| COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH CARTILAGE OLIGOMERIC MATRIX PROTEIN (COMP) MUTATIONSFiled as ULTRAGENYX PHARMACEUTICAL, INC.2024-10-11TING TIM CHIU | pending |
| MODIFIED BATCH AAV PRODUCTION SYSTEMS AND METHODSC12N 7/00, C12N 15/86, C12N 5/0018, C12N 15/87, C12N2500/60, C12N2750/14122, C12N2750/14143, C12N2750/14151, C12N2750/14152Filed as Ultragenyx Pharmaceutical Inc.2024-09-06Cameron Tage Fulco | pending |
| METHODS OF PRODUCING CDKL5 PROTEINS AND USES OF THE SAMEFiled as ULTRAGENYX PHARMACEUTICAL INC.2024-08-30MARK FOX | pending |
| COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH BSEP DEFICIENCYFiled as ULTRAGENYX PHARMACEUTICAL INC.2024-07-23MARGARET CAROLINE WRIGHT | pending |
| COMPOSITIONS AND METHODS FOR REDUCING HOST CELL PROTEINS IN RECOMBINANT ADENO-ASSOCIATED VIRUS PREPARATIONSFiled as ULTRAGENYX PHARMACEUTICAL INC.2024-06-20WENJUN DI | pending |
| FORMULATIONS COMPRISING RECOMBINANT AAV AND METHODS OF ADMINISTERING THE SAMEFiled as ULTRAGENYX PHARMACEUTICAL INC.2024-05-17HEATHER LAU | pending |
| MULTI-STEP FILTRATION AND CLARIFICATION METHODS FOR RECOMBINANT ADENO-ASSOCIATED VIRUS PURIFICATIONFiled as Ultragenyx Pharmaceutical Inc.2024-05-09Dennis Perry Chen | pending |
| ENGINEERED PRODUCER CELL LINES AND METHODS OF MAKING AND USING THE SAMEC12N 7/00, C12N 15/86, C12N2310/20, C12N 15/11, C12N 15/113, C12N 15/85, C12N2310/14, C12N2310/315, C12N2310/321, C12N2750/14143, C12N2750/14152, C12Q 1/6869Filed as Ultragenyx Pharmaceutical Inc.2024-05-09Aubrey R. Tiernan | pending |
| ENGINEERED CELL LINES FOR INCREASED PRODUCTION OF RECOMBINANT ADENO-ASSOCIATED VIRUS (RAAV)C12N 7/00, C12N 5/00, C12N 15/113, C12N2310/14, C12N2510/02, C12N2750/14121, C12N2750/14152Filed as Ultragenyx Pharmaceutical Inc.2024-04-26Nicholas Richards | pending |
| MULTI-STEP FILTRATION AND CLARIFICATION METHODS FOR RECOMBINANT ADENO-ASSOCIATED VIRUS PURIFICATIONFiled as Ultragenyx Pharmaceutical Inc.2024-04-22Dennis Perry Chen | pending |
| DOSING REGIMENS FOR ANTISENSE TREATMENT OF ANGELMAN SYNDROMEFiled as Ultragenyx Pharmaceutical Inc.2024-04-11Olukemi Ajayi OLUGEMO | pending |
| METHODS OF USING ANTI-SCLEROSTIN ANTIBODIES IN TREATMENT OF OSTEOGENESIS IMPERFECTAC07K 16/22, A61P 19/00, A61P 19/08, A61K2039/505, A61K2039/545, C07K2317/24Filed as Ultragenyx Pharmaceutical Inc.2024-03-28Alastair MacKinnon | pending |
| HUMAN FGF23-BINDING ANTIBODIES WITH IMPROVED AFFINITY AND EFFICACYFiled as ULTRAGENYX PHARMACEUTICAL INC.2024-03-08MARK FOX | pending |
| METHODS OF HEAT INACTIVATION OF ADENOVIRUSA61K 35/761, C12N 7/00, C12N 15/85, C12N 15/86, C12N2523/00, C12N2710/10043, C12N2710/10361, C12N2750/14143, C12N2750/14151, C12N2750/14161Filed as Ultragenyx Pharmaceutical Inc.2024-02-29Christopher J. Morrison | pending |
| CRYSTALLINE FORMS OF SIALIC ACID DERIVATIVES AND METHODS FOR THEIR USEFiled as ULTRAGENYX PHARMACEUTICAL INC.2024-02-16JEAN CAROL BAUM | pending |
| RECOMBINANT AAV FORMULATIONSC12N 15/86, A61K 9/0019, A61K 47/26, A61K 47/34, C12N2750/14132, C12N2750/14143Filed as Ultragenyx Pharmaceutical Inc.2024-02-16Julie Yu Wei | pending |
| ANION-EXCHANGE CHROMATOGRAPHY METHODS FOR PURIFICATION OF RECOMBINANT ADENO-ASSOCIATED VIRUSESC12N 7/00, C12N 15/86, B01D 15/1896, B01D 15/166, B01D 15/363, B01D 15/426, C12N2750/14123, C12N2750/14143, C12N2750/14151Filed as Ultragenyx Pharmaceutical Inc.2024-02-15Dennis Perry Chen | pending |
| COMPOSITIONS AND METHODS FOR TREATING A MUSCULAR DYSTROPHYFiled as Ultragenyx Pharmaceutical Inc.2024-02-08Matthew Scott Fuller | pending |
| LYOPHILIZED LIPID NANOPARTICLES AND METHODS OF THEIR USEFiled as Ultragenyx Pharmaceutical, Inc.2024-02-08ISAIAS PRADO | pending |
| HUMAN FGF23-BINDING ANTIBODIES WITH IMPROVED AFFINITY AND EFFICACYFiled as Ultragenyx Pharmaceutical Inc.2024-02-01Mark Fox | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on RARE
Company overviewEverything on RARE in one place, with the price.SEC filingsWhat RARE's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat RARE's own officers and directors buy and sell.Planned salesSales RARE insiders have filed notice of.Who owns itEvery manager reporting a position in RARE.Funds holding itWhich funds and ETFs hold RARE, and how big a bet.LobbyingWhat RARE spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on RARE's account, and who they worked for.